Research on Repaglinide in Insulin Glargine Combined with Newly Diagnosed Type 2 Diabetes

Objective: To investigate the effect of insulin glargine combined with repaglinide in the treatment of newly diagnosed type 2 diabetes,as well as on the function of islet β cell effect.Method: 80 patients with newly diagnosed type 2 diabetic patients,were randomly divided into the observation group and the control group,40 cases in each group,the groups were observed given repaglinide tablet and insulin glargine,the control group was given glipizide and insulin glargine,two groups were observed in patients with impaired fasting glucose(FPG),2h postprandial plasma glucose(2hPG),glycosylated hemoglobin(HbA1C),as well as the application of first phase insulin secretion and homeostasis model assessment of islet B cell function.Result: In the observation group,the total effective rate was 95%,It was significantly higher than that in control group 80%,the difference was statistically significant(P 0.05);after 6 months of treatment,two groups of patients with FPG,2hPG and HbA1C water decreased,but the observation group decreased more obviously(P 0.05),and in the observation group,FINS fasting C peptide,AIR and HOMA beta F is better than that of control group(P 0.05).In the observation group,hypoglycemia occurred at a rate of 7.50%,lower than 30% in the control group,the difference was statistically significant(P 0.05).Conclusion: Insulin glargine plus repaglinide can effectively control in newly diagnosed type 2 diabetic patients blood glucose,maintain and restore the function of islet β cell,hypoglycemia incidence is low,safe and reliable,worthy of clinical application.